Guzzi,
I would suspect that a BP won't see the value here until the EDEN is available. Investing billions to run new trials is of little value if you cannot produce product, I don't believe more money would accelerate the process very much. The demand will be great once they have an approval and the EDEN available to make it. More trials will be added by that time, but the key will be cranking out the EDEN's as they're gaining approvals throughout the world.
A BP isn't going to offer $10, or even $5 a share for a company that's trading at $1 or less. When LP gets the price up to roughly 50% of what she wants from a BP in an equity partnership, perhaps it will come to pass. I can't say what that will be, or if it ever will be. I would suspect that if LP wishes to, she can raise substantial money in other ways that involve how the EDEN is handled. The real question is, does LP really want either a BP partner, or buyer, or would she truly like to keep the company independent of them. I suspect that she can call the shots and do as she wishes.
If NWBO is to remain completely independent, perhaps with collaborative trials with many others, if our vaccines truly prove effective in many solid cancers, NWBO could grow to rival the massive biotech's, like AMGN.
One of my biggest mistakes over 30 years ago was not buying AMGN when it was around $15 in the early 1990's. By the end of that decade it ended at around $70, but during that time it split a total of 48 to 1. That's the same sort of growth that's possible right here, but because we've already got over a billion shares out, I doubt if we'd have a split, though it may be possible once the share price is well into triple digits. With all it's splits, AMGN still has under 600 million shares outstanding, I'd not be surprised if they did a 2 for 1 at some time in the future, in the 1990's they split practically every time they approached triple digits.
Gary
Bullish
Market Data 
Markets 
AI
